Paradigm Biopharmaceuticals Enters Phase Three Trial Dosing Phase for Knee Osteoarthritis Pain in the September Quarter
MT Newswires Live
Oct 30, 2025
Paradigm Biopharmaceuticals (ASX:PAR) said it entered the dosing phase of its global phase three clinical trial evaluating injectable pentosan polysulfate sodium for pain associated with knee osteoarthritis, with participants randomized and dosed in both Australia and the US, according to a Thursday Australian bourse filing.
The total target enrollment remains 466 participants, with the interim analysis planned once 50% of participants reach day 112, which is anticipated to occur in mid-2026.
All selected trial sites across Australia and the US are expected to be active and recruiting by early November. It continues to evaluate the potential inclusion of additional sites outside these two countries to further support recruitment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.